Polarean Imaging plc (PLLWF) Prix

Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.